Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01397578 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT01397578 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 91 participants.
The verdict
NCT01397578, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.
Interventions
- DRUG placebo
- DRUG MABT5102A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2011-08-31 |
| Est. Completion | 2014-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01397578
The ClinicalTrials.gov registry entry for NCT01397578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01397578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01397578 about?
NCT01397578 is a clinical study titled "A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease". This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.
What is the current status of trial NCT01397578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2011-08-31. Estimated completion is 2014-04-30.
What interventions are being tested in trial NCT01397578?
The interventions under investigation include: placebo (DRUG), MABT5102A (DRUG).
Who is sponsoring clinical trial NCT01397578?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.